Dabigatran etexilate
- Generic Name
- Dabigatran etexilate
- Brand Names
- Pradaxa
- Drug Type
- Small Molecule
- Chemical Formula
- C34H41N7O5
- CAS Number
- 211915-06-9
- Unique Ingredient Identifier
- 2E18WX195X
- Background
Dabigatran etexilate is an oral prodrug that is hydrolyzed to the competitive and reversible direct thrombin inhibitor dabigatran. Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients in whom anticoagulation therapy is indicated. In contrast to warfarin, because its anticoagulant effects are predictable, lab monit...
- Indication
Dabigatran etexilate is available in both oral pellet and capsule form. Dabigatran etexilate pellets are indicated for the treatment of venous thromboembolic events (VTE) in pediatric patients between three months and 12 years of age who have been treated with a parenteral anticoagulant for at least 5 days. They are also indicated in the same age group to re...
- Associated Conditions
- Deep Vein Thrombosis, Deep vein thrombosis recurrent, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Recurrent Venous Thromboembolism, Stroke, Systemic Embolism, Venous Thromboembolism
- Associated Therapies
- -
Dabigatran in Patients With Atrial Fibrillation and Mitral Biological Prostheses
- Conditions
- Interventions
- First Posted Date
- 2017-06-12
- Last Posted Date
- 2017-06-12
- Target Recruit Count
- 40
- Registration Number
- NCT03183843
- Locations
- 🇷🇺
Research Institute for Complex Problems of Cardiovascular Diseases, Kemerovo, Russian Federation
Pradaxa Tablet Proton Pump Inhibitor (PPI) Bioavailability (BA) Study in Japan
- Conditions
- Interventions
- First Posted Date
- 2017-05-08
- Last Posted Date
- 2019-01-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT03143166
- Locations
- 🇯🇵
Souseikai Hakata Clinic, Fukuoka, Fukuoka, Japan
Study to Investigate the Pharmacokinetics (PK) and Pharmacodynamics (PD) of Idarucizumab in Chinese Healthy Male and Female Volunteers Who Had Taken Dabigatran Etexilate and Whose Plasma Concentrations of Dabigatran Were at or Close to Steady State
- Conditions
- Interventions
- First Posted Date
- 2017-03-22
- Last Posted Date
- 2019-03-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 12
- Registration Number
- NCT03086356
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, China
Bioequivalence of Tablet Formulation of Dabigatran Etexilate Compared to Commercial Capsule Formulation Following Oral Administration in Healthy Male Subjects
- First Posted Date
- 2017-03-03
- Last Posted Date
- 2019-01-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 160
- Registration Number
- NCT03070171
- Locations
- 🇯🇵
SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan
Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation
- Conditions
- Interventions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2021-09-02
- Lead Sponsor
- Intermountain Health Care, Inc.
- Target Recruit Count
- 101
- Registration Number
- NCT03061006
- Locations
- 🇺🇸
Intermountain Heart Institute, Murray, Utah, United States
Validation of Predictors of OAC Initiation Using EMR Data
- First Posted Date
- 2016-12-30
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 140187
- Registration Number
- NCT03006341
- Locations
- 🇺🇸
Brigham & Women's Hospital, Boston, Massachusetts, United States
Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism undergoIng Endovascular Mechanical Fragmentation and Thrombolytic Therapy
- First Posted Date
- 2016-12-01
- Last Posted Date
- 2016-12-20
- Target Recruit Count
- 200
- Registration Number
- NCT02979561
- Locations
- 🇷🇺
Federal State Institution Academician E.N.Meshalkin Novosibirsk State Research Institute Of Circulation Pathology Rusmedtechnology, Novosibirsk, Russian Federation
A Clinical Trial Comparing Efficacy and Safety of Dabigatran Etexilate With Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis (RE-SPECT CVT)
- First Posted Date
- 2016-09-23
- Last Posted Date
- 2019-08-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 120
- Registration Number
- NCT02913326
- Locations
- 🇮🇳
Caritas Hospital, Kottayam, India
🇮🇳Mazumdar Shaw Medical centre, Bangalore, India
🇮🇳Nizam's Institute of Medical Sciences, Hyderabad, India
Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation
- Conditions
- Interventions
- First Posted Date
- 2016-01-28
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- National Cheng-Kung University Hospital
- Target Recruit Count
- 3672
- Registration Number
- NCT02666157
- Locations
- 🇨🇳
E-DA Hospital, Kaohsiung, Taiwan
🇨🇳National Cheng Kung University Hospital, Tainan, Tainan City, Taiwan
🇨🇳Tainan Hospital Ministry of Health and Welfare, Tainan, Tainan City, Taiwan
The Efficacy and Safety Study of Dabigatran and Warfarin to Non-valvular Atrial Fibrillation Patients
- Conditions
- Interventions
- First Posted Date
- 2016-01-05
- Last Posted Date
- 2016-01-05
- Target Recruit Count
- 210
- Registration Number
- NCT02646267
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.